Danlin Xu

2.3k total citations · 1 hit paper
18 papers, 1.7k citations indexed

About

Danlin Xu is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Molecular Biology. According to data from OpenAlex, Danlin Xu has authored 18 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Radiology, Nuclear Medicine and Imaging, 5 papers in Immunology and 4 papers in Molecular Biology. Recurrent topics in Danlin Xu's work include Monoclonal and Polyclonal Antibodies Research (6 papers), T-cell and B-cell Immunology (3 papers) and Inhalation and Respiratory Drug Delivery (2 papers). Danlin Xu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), T-cell and B-cell Immunology (3 papers) and Inhalation and Respiratory Drug Delivery (2 papers). Danlin Xu collaborates with scholars based in United States, China and Austria. Danlin Xu's co-authors include Robert A. Zivin, Jeffrey A. Bluestone, Julie Auger, Lesley Taylor, David M. Harlan, David Donaldson, William Hagopian, Stephen E. Gitelman, Kevan C. Herold and Linda K. Jolliffe and has published in prestigious journals such as Nature, New England Journal of Medicine and Nucleic Acids Research.

In The Last Decade

Danlin Xu

15 papers receiving 1.7k citations

Hit Papers

Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes... 2002 2026 2010 2018 2002 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus
    2002 903 citations Kevan C. Herold, William Hagopian et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Danlin Xu United States 9 973 850 700 617 274 18 1.7k
Menno van Lummel Netherlands 20 582 0.6× 435 0.5× 454 0.6× 283 0.5× 175 0.6× 26 1.4k
Jena D. French United States 16 175 0.2× 650 0.8× 88 0.1× 762 1.2× 54 0.2× 27 1.7k
Susan Rostami United States 19 815 0.8× 942 1.1× 673 1.0× 305 0.5× 54 0.2× 39 1.6k
C. Bigorgne France 13 93 0.1× 161 0.2× 315 0.5× 439 0.7× 162 0.6× 33 1.2k
Virginia Lepage France 17 218 0.2× 464 0.5× 136 0.2× 58 0.1× 90 0.3× 26 1.1k
Anita Dobyszuk Poland 5 298 0.3× 1.1k 1.3× 202 0.3× 109 0.2× 17 0.1× 6 1.4k
Hajime Yamagata Japan 16 139 0.1× 437 0.5× 253 0.4× 52 0.1× 399 1.5× 35 1.5k
Chun Jing Wang United Kingdom 14 303 0.3× 891 1.0× 123 0.2× 91 0.1× 28 0.1× 20 1.1k
Kesley Attridge United Kingdom 9 252 0.3× 1.4k 1.7× 101 0.1× 56 0.1× 40 0.1× 12 1.8k
Per Marits Sweden 19 164 0.2× 663 0.8× 267 0.4× 47 0.1× 34 0.1× 37 1.1k

Countries citing papers authored by Danlin Xu

Since Specialization
Citations

This map shows the geographic impact of Danlin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Danlin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Danlin Xu more than expected).

Fields of papers citing papers by Danlin Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Danlin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Danlin Xu. The network helps show where Danlin Xu may publish in the future.

Co-authorship network of co-authors of Danlin Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Danlin Xu. A scholar is included among the top collaborators of Danlin Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Danlin Xu. Danlin Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Wang, Bo, et al.. (2025). Population Pharmacokinetics and AUC‐Based Dose Optimization of Vancomycin in Chinese Neonates. Journal of Clinical Pharmacy and Therapeutics. 2025(1).
2.
3.
Lake, Stephen, Laurent Servais, Craig Campbell, et al.. (2023). P22 WVE-N531 yields 53% mean exon 53 skipping in skeletal muscle of boys with Duchenne muscular dystrophy (DMD) after three biweekly doses. Neuromuscular Disorders. 33. S102–S102. 2 indexed citations
4.
5.
Han, David, Carlos Fernández-Llatas, Eugene J. Sullivan, et al.. (2016). Single dose pharmacokinetics of C16TR for Inhalation (INS1009) vs treprostinil inhalation solution. PA2398–PA2398. 3 indexed citations
6.
Han, David, Carlos Fernández‐Peña, Eugene J. Sullivan, et al.. (2016). Safety and pharmacokinetics study of a single ascending dose of C16TR for inhalation (INS1009). PA2403–PA2403. 6 indexed citations
7.
Kopp, Tamara, Elisabeth Riedl, Christine Bangert, et al.. (2015). Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature. 521(7551). 222–226. 165 indexed citations
8.
Kosoglou, Teddy, James Hubbell, David L. Cutler, et al.. (2013). Hypothalamic-Pituitary-Adrenal Axis Effects of Mometasone Furoate/Formoterol Fumarate vs Fluticasone Propionate/Salmeterol Administered Through Metered-Dose Inhaler. CHEST Journal. 144(6). 1795–1802. 4 indexed citations
9.
Xu, Danlin, Ze’ev Gechtman, Robert A. Dodds, et al.. (2006). Potential involvement of BMP receptor type IB activation in a synergistic effect of chondrogenic promotion between rhTGFβ3 and rhGDF5 or rhBMP7 in human mesenchymal stem cells. Growth Factors. 24(4). 268–278. 24 indexed citations
10.
Utset, Tammy O., Julie Auger, Donna Peace, et al.. (2002). Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial.. PubMed. 29(9). 1907–13. 98 indexed citations
11.
Herold, Kevan C., William Hagopian, Julie Auger, et al.. (2002). Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus. New England Journal of Medicine. 346(22). 1692–1698. 903 indexed citations breakdown →
12.
Xu, Danlin, Maria-Luisa Alegre, Annette L. Rothermel, et al.. (2000). In Vitro Characterization of Five Humanized OKT3 Effector Function Variant Antibodies. Cellular Immunology. 200(1). 16–26. 177 indexed citations
13.
Woodle, E. Steve, Danlin Xu, Robert A. Zivin, et al.. (1999). PHASE I TRIAL OF A HUMANIZED, Fc RECEPTOR NONBINDING OKT3 ANTIBODY, huOKT3??1 (Ala-Ala) IN THE TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION. Transplantation. 68(5). 608–616. 140 indexed citations
14.
Woodle, E. Steve, Jeffrey A. Bluestone, Robert A. Zivin, et al.. (1998). Humanized, Nonmitogenic OKT3 Antibody, huOKT3γ(Ala-Ala): Initial Clinical Experience. Transplantation Proceedings. 30(4). 1369–1370. 30 indexed citations
15.
Alegre, Maria‐Luisa, Laura Peterson, Danlin Xu, et al.. (1994). A NON-ACTIVATING “HUMANIZED” ANTI-CD3 MONOCLONAL ANTIBODY RETAINS IMMUNOSUPPRESSIVE PROPERTIES IN VIVO. Transplantation. 57(11). 1537–1543. 3 indexed citations
16.
Adair, John R., D. S. Athwal, Mark Bodmer, et al.. (1994). Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Human Antibodies. 5(1-2). 41–47. 50 indexed citations
17.
Alegre, Maria‐Luisa, Laura J. Peterson, Danlin Xu, et al.. (1994). A NON-ACTIVATING “HUMANIZED” ANTI-CD3 MONOCLONAL ANTIBODY RETAINS IMMUNOSUPPRESSIVE PROPERTIES IN VIVO. Transplantation. 57(11). 1537–1543. 132 indexed citations
18.
Xu, Danlin, et al.. (1990). Nucleotide sequence of a new BALB/c mouse kappa light chain variable region gene. Nucleic Acids Research. 18(7). 1912–1912. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Menno van Lummel Breakdown of academic impact, for papers by Jena D. French Breakdown of academic impact, for papers by Susan Rostami Breakdown of academic impact, for papers by C. Bigorgne Breakdown of academic impact, for papers by Virginia Lepage Breakdown of academic impact, for papers by Anita Dobyszuk Breakdown of academic impact, for papers by Hajime Yamagata Breakdown of academic impact, for papers by Chun Jing Wang Breakdown of academic impact, for papers by Kesley Attridge Breakdown of academic impact, for papers by Per Marits
Rankless by CCL
2026